Johnson & Johnson $JNJ Shares Sold by Lee Danner & Bass Inc.

Lee Danner & Bass Inc. cut its position in Johnson & Johnson (NYSE:JNJ) by 5.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 109,082 shares of the company’s stock after selling 6,098 shares during the period. Johnson & Johnson makes up 1.3% of Lee Danner & Bass Inc.’s holdings, making the stock its 15th largest position. Lee Danner & Bass Inc.’s holdings in Johnson & Johnson were worth $16,662,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Johnson & Johnson by 1.9% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,157,669 shares of the company’s stock valued at $940,584,000 after acquiring an additional 113,356 shares during the last quarter. West Michigan Advisors LLC boosted its holdings in Johnson & Johnson by 38.9% in the second quarter. West Michigan Advisors LLC now owns 7,054 shares of the company’s stock valued at $1,077,000 after purchasing an additional 1,976 shares during the period. Kathleen S. Wright Associates Inc. boosted its holdings in Johnson & Johnson by 3.1% in the second quarter. Kathleen S. Wright Associates Inc. now owns 7,500 shares of the company’s stock valued at $1,225,000 after purchasing an additional 227 shares during the period. Moloney Securities Asset Management LLC lifted its holdings in Johnson & Johnson by 4.2% during the 2nd quarter. Moloney Securities Asset Management LLC now owns 37,079 shares of the company’s stock worth $5,664,000 after buying an additional 1,510 shares during the last quarter. Finally, Opus Capital Group LLC lifted its holdings in Johnson & Johnson by 9.9% during the 2nd quarter. Opus Capital Group LLC now owns 6,016 shares of the company’s stock worth $919,000 after buying an additional 540 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on JNJ. Bank of America boosted their target price on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a report on Wednesday, October 15th. JPMorgan Chase & Co. boosted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. UBS Group increased their target price on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Finally, Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ opened at $190.38 on Friday. The business’s 50 day moving average is $182.26 and its 200-day moving average is $166.13. The stock has a market cap of $458.69 billion, a PE ratio of 18.38, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40. The company has a current ratio of 1.07, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.